Department of Dermatology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China
Institute of Dermatology, Anhui Medical University, Hefei, Anhui Province, China
Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, Anhui Province, China
State Key Laboratory Incubation Base of Dermatology, Anhui Medical University, Hefei, Anhui Province, China
Key Laboratory of Major Autoimmune Diseases, Hefei, Anhui Province, China
Boao Super Hospital Dermatology Center, Qionghai, Hainan Province, China
These authors contributed equally.
Background: The efficacy and safety of secukinumab, an interleukin-17 inhibitor, as systemic treatment for patients with moderate-to-severe psoriasis have been demonstrated, but real-world data pertaining to this is limited in China. Objective: To evaluate the efficacy and safety of secukinumab in clinical practice in Chinese psoriasis patients with or without psoriatic arthritis (PsA) and identify potential baseline factors that affect the response of patients to secukinumab treatment. Materials & Methods: Data from 81 patients treated with secukinumab for at least 16 weeks were analysed in a retrospective observational study. Results: After 16 weeks of treatment with secukinumab, 91.1%, 73%, and 38.3% of patients achieved a PASI 75 (75% improvement based on the Psoriasis Area and Severity Index), PASI 90, and PASI 100, respectively. A significant improvement in the quality of life of patients was also observed. Notably, baseline factors, such as young age, lower BMI, no scalp involvement and absence of concomitant PsA, were associated with better clinical response to secukinumab. Approximately 42% of patients (34/81) experienced adverse events, of which the most common was pruritus. Conclusion: The results demonstrated that secukinumab appears to be an effective treatment alternative for the majority of Chinese plaque psoriasis patients. Baseline factors, including age, BMI, scalp involvement and concomitant presence of PsA, were associated with response to secukinumab.